Photo: Viz.ai
July 9, 2026 — Viz.ai has announced a collaboration with Cortechs.ai to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its neuro offerings.
The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale.
"This collaboration with Cortechs.ai extends that commitment into neurodegenerative disease, an area with profound unmet need and enormous potential — particularly where earlier patient identification and disease characterization can meaningfully change the treatment trajectory," said said Dr. Tim Showalter, chief medical officer at Viz.ai. "We see this as the foundation for something much bigger, and we're just getting started."
Treating Neurodegenerative Diseases
With an established footprint of nearly 2,000 U.S. hospitals, Viz.ai is uniquely positioned alongside Cortechs.ai to ensure patients with neurodegenerative disease reach the right care, faster.
“Cortechs.ai is building NeuroQuant into the leading platform for neuro quantification and analysis by providing the trusted intelligence layer that enables healthcare innovators to seamlessly integrate clinically validated quantitative imaging into their own solutions,” said Kyle Frye, CEO at Cortechs.ai. “We believe the future of healthcare AI will be built on connected platforms, not isolated point solutions. Our partnership with Viz.ai is a powerful example of that vision, combining Viz.ai’s care coordination platform with the trusted quantitative insights of NeuroQuant and NeuroQuant MS platforms to accelerate innovation, enhance clinical decision-making, and ultimately improve outcomes for patients.”
July 02, 2026 
